Drug Trial Radar · NCT07782775
A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jun 19, 2026
Primary completion
Sep 23, 2026
Study completion Sep 23, 2026
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to compare the amount of efgartigimod in the blood over time after it is injected via Prefilled syringe (PFS) and Autoinjector (AI). The study will comprise 2 study periods of 3 weeks each. Each participant receives both efgartigimod PH20 SC AI and PFS treatments, in a different order. Participants will be in the study for up to approximately 9 weeks.
Conditions
- Healthy Volunteer
- Healthy Adult Participants
Interventions
Efgartigimod PH20 SC via PFSBiological
Subcutaneous injection of empasiprubart via Prefilled syringe (PFS)
Efgartigimod PH20 SC via AIBiological
Subcutaneous injection of empasiprubart via Autoinjector (AI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary PK parameter: CmaxTime frame: Up to 9 weeks
- Primary PK parameter: AUC0-infTime frame: Up to 9 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences
Montreal, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.